Free Trial
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Atea Pharmaceuticals logo
$2.90 +0.08 (+2.84%)
Closing price 04:00 PM Eastern
Extended Trading
$2.87 -0.03 (-1.03%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Advanced

Key Stats

Today's Range
$2.81
$2.92
50-Day Range
$2.82
$3.80
52-Week Range
$2.45
$4.02
Volume
720,563 shs
Average Volume
268,218 shs
Market Capitalization
$230.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Atea Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

AVIR MarketRank™: 

Atea Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 742nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atea Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Atea Pharmaceuticals has a consensus price target of $6.00, representing about 106.9% upside from its current price of $2.90.

  • Amount of Analyst Coverage

    Atea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Atea Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.79) per share.

  • Price to Book Value per Share Ratio

    Atea Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Atea Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.55% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently increased by 4.78%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Atea Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Atea Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.55% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently increased by 4.78%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      18.10% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Atea Pharmaceuticals' insider trading history.
    Receive AVIR Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    AVIR Stock News Headlines

    The Tiny Stock Set to Soar with Musk's AI Ambitions
    The Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires in history, one tiny AI stock is flying under the radar. While you can't invest directly, we've pinpointed a stock poised to benefit immensely from his plans.tc pixel
    Atea (AVIR) Q2 Loss Narrows 8%
    See More Headlines

    AVIR Stock Analysis - Frequently Asked Questions

    Atea Pharmaceuticals' stock was trading at $3.35 at the beginning of the year. Since then, AVIR shares have decreased by 13.4% and is now trading at $2.90.

    Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02.
    Read the conference call transcript
    .

    Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.

    Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO).

    Company Calendar

    Last Earnings
    8/07/2025
    Today
    10/03/2025
    Next Earnings (Estimated)
    11/06/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:AVIR
    CIK
    1593899
    Fax
    N/A
    Employees
    70
    Year Founded
    2014

    Price Target and Rating

    High Price Target
    $6.00
    Low Price Target
    $6.00
    Potential Upside/Downside
    +106.9%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.61)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$168.38 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -32.55%
    Return on Assets
    -30.47%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    19.17
    Quick Ratio
    19.17

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $5.20 per share
    Price / Book
    0.56

    Miscellaneous

    Outstanding Shares
    79,360,000
    Free Float
    64,994,000
    Market Cap
    $230.14 million
    Optionable
    Optionable
    Beta
    0.22

    Social Links

    The Best High-Yield Dividend Stocks for 2025 Cover

    Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

    Get This Free Report

    This page (NASDAQ:AVIR) was last updated on 10/3/2025 by MarketBeat.com Staff
    From Our Partners